Abstract: The present disclosure relates to methods for preparing a dried preparation comprising lipids and therapeutic agents whereby the therapeutic agents are incorporated both before and after sizing of lipid vesicle particles to a mean particle size of ?120 nm and a polydispersity index (PDI) of ?0.1. The present application also provides stable, water-free pharmaceutical compositions comprising one or more lipid-based structures having a single layer lipid assembly, at least two therapeutic agents, and a hydrophobic carrier, as well as methods of treatment, uses and kits relating thereto, such as for example for inducing an antibody and/or CTL immune response.

Abstract: The present disclosure relates to methods for preparing a dried preparation comprising lipids and a therapeutic agent by using lipid vesicle particles having a mean particle size of ?120 nm and a polydispersity index (PDI) of ?0.1. The present application also provides stable, water-free pharmaceutical compositions comprising one or more lipid-based structures having a single layer lipid assembly, at least one therapeutic agent, and a hydrophobic carrier, as well as methods of treatment, uses and kits relating thereto, such as for example for inducing an antibody and/or CTL immune response.

Abstract: The present invention relates to new compounds of formula (I) wherein R1 to R9, X, p and n are defined as in claim 1, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

Abstract: Compounds of formula: wherein R1 and R2 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.